Physionic
Combining bimagrumab with GLP-1 agonists reduces fat and preserves muscle, but does not significantly build muscle in humans.
The combination effectively reduces body fat and prevents muscle loss, but clinical trials show no meaningful muscle growth in humans.
We checked the science
our breakdown of the video
10 claims, each mapped to its moment in the video
Using a GLP-1 receptor agonist together with a myostatin pathway inhibitor leads to a reduction in body fat and either no change or an increase in lean tissue mass.
Multiple causal studies (randomized trials and reviews) support this claim.
When bimagrumab is taken together with a GLP-1 receptor agonist, blood sugar levels decrease more and markers of systemic inflammation are lower than when the GLP-1 receptor agonist is taken by itself.
Strong evidence from clinical studies backs this claim.
When the inactive form of myostatin is blocked, it cannot become active, and muscle growth is not suppressed.
Multiple causal studies (randomized trials and reviews) support this claim.
Myostatin is a protein in the body that reduces the growth of skeletal muscle.
Multiple causal studies (randomized trials and reviews) support this claim.
Bimagrumab, a specific antibody, decreases body fat without requiring the presence or activity of GLP-1 receptor agonists.
Multiple causal studies (randomized trials and reviews) support this claim.
Bimagrumab blocks specific proteins called activin A and GDF8 that control the growth and maintenance of muscle and fat tissue.
Multiple causal studies (randomized trials and reviews) support this claim.
When taken with a GLP-1 receptor agonist, apitegromab increases fat loss compared to the agonist alone. When taken by itself, apitegromab does not reduce fat mass.
Multiple causal studies (randomized trials and reviews) support this claim.
When bimagrumab and a GLP-1 receptor agonist are taken together, fat mass decreases more than when either drug is taken alone.
Multiple causal studies (randomized trials and reviews) support this claim.
During weight loss, bimagrumab leads to an increase in lean mass, while apitegromab slows the loss of lean mass.
Multiple causal studies (randomized trials and reviews) support this claim.
Myostatin-inhibiting antibodies increase muscle mass in animals by blocking biological signals that normally restrict muscle growth.
Multiple causal studies (randomized trials and reviews) support this claim.
Key Takeaways
Summary
Based on the video transcript only.
- 1Fat loss is real: bimagrumab alone or with GLP-1 drugs like tirzepatide can cut body fat nearly in half.
- 2Muscle gain is not: no meaningful increase in muscle size or strength was seen in any human trial, even though the theory says it should work.
- 3The antibodies block proteins that limit muscle growth, but in people, they only slightly slow muscle loss—not rebuild it.
- 4Side effects like diarrhea, acne, and muscle spasms are common with bimagrumab, making the trade-off questionable.
- 5Resistance training remains the only proven way to build muscle while losing fat—no pill or injection replaces it.
Related videos
Physionic
14 Cheese Studies: A Surprising Relationship with Death
Physionic
‘High Dose Vitamin D’s Steroid-like Effect! Crazy!’
Physionic
This New Protein Study just Changed how we Think about Protein!
Physionic
This Peptide Reverses Osteoarthritis!
Physionic